Eltanexor Plus Inqovi
A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 80 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Nucleoside Metabolic Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1733
- NCT Identifier
- NCT05918055
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.